Holen Sie sich die Stockscreener-App
52.27
32.39%
12.78
Soleno Therapeutics Inc Aktie (SLNO) Neueste Nachrichten
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B to Expand Rare Disease Portfolio - Oncodaily
Pharmaceutical Stocks To Watch NowApril 6th - MarketBeat
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Soleno Therapeutics, Inc. (NASDAQ: SLNO) - prnewswire.com
Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9B - National Today
Soleno Stock Soars on $2.9 Billion Neurocrine Buyout. Its Hunger Drug Is a Different Weight-Loss Play. - Barron's
Soleno Therapeutics Soars as Neurocrine Unveils $2.9B All-Cash Buyout at $53 a Share - Yahoo Finance
Are Options Traders Betting on a Big Move in Soleno Therapeutics Stock? - TradingView
These Stocks Are Today’s Movers: Seagate, Micron, Tesla, Kratos, Strategy, Soleno, Viridian, and More - Barron's
Soleno Therapeutics Faces Investor Lawsuit Over Alleged Safety Concerns - National Today
Neurocrine Biosciences Details $2.9B Soleno Buyout, Touts Vykat XR as Potential Blockbuster - Yahoo Finance
Soleno Therapeutics Faces Shareholder Lawsuit Investigation - National Today
Bronstein, Gewirtz & Grossman LLC Urges Soleno - globenewswire.com
Neurocrine Biosciences, Inc. entered into a definitive agreement to acquire Soleno Therapeutics, Inc. from Anish Bhatnagar, James Mackaness, and others for $2.8 billion. - marketscreener.com
Soleno Therapeutics Faces Price Target Cut Amid Slower Vykat XR Launch - timothysykes.com
Neurocrine Is Making a $2.9 Billion Bet on a New Kind of Drug - inc.com
Shareholder Alert: The Ademi Firm investigates whether Soleno Th - gurufocus.com
Soleno Therapeutics (NASDAQ:SLNO) Shares Gap UpStill a Buy? - MarketBeat
Shareholder Alert: The Ademi Firm investigates whether Soleno Therapeutics Inc.'s Transaction with Neurocrine is Fair to Public Shareholders - prnewswire.com
Soleno Therapeutics jumps on $2.9B all-cash buyout deal at $53/share - Quiver Quantitative
Neurocrine to Buy Soleno, Nabbing Drug for Relentless Hunger Disorder - WSJ
Soleno Therapeutics' (SLNO) Neutral Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Soleno Therapeutics Stock Skyrockets 33% After Neurocrine Biosciences Announces Acquisition Deal - TIKR.com
Soleno Therapeutics shares jump nearly 40% on $2.9 billion takeout deal | 2026-04-06 | Investing News - Stockhouse
Soleno Therapeutics, Playtika Holding And Other Big Stocks Moving Higher On Monday - Benzinga
Neurocrine, eying ‘blockbuster in the making,’ strikes its largest-ever M&A deal with $2.9B Soleno buyout - Fierce Pharma
Market movers: Virgin Galactic, Soleno Therapeutics, Medicus Pharma... - Proactive financial news
Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal - Axios
Neuroendocrine Bioscience spends 2.9 billion US dollars to acquire Soleno and enters the metabolic disease field. - 富途牛牛
Neurocrine Enters $2.9 Billion Agreement to Acquire Soleno Therapeutics - pharmexec.com
Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. - Barron's
Neurocrine to Buy Soleno Therapeutics for $2.9 Billion - Bloomberg.com
SLNO Stock Alert: Halper Sadeh LLC is Investigating Whether Soleno Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - marketscreener.com
Neurocrine Biosciences to acquire Soleno Therapeutics in $2.9B deal - Yahoo! Finance Canada
Soleno Therapeutics (SLNO) still appears attractive despite slower US launch ramp projections - MSN
Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9 billion - MLex
Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout - PharmaLive
Oppenheimer’s Bold Forecast: Soleno Sees $80 Price Target Amid Slower Vykat XR Launch - timothysykes.com
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal - marketscreener.com
Soleno Therapeutics (SLNO) Stock Jumps 30% on Neurocrine $2.5B Buyout Report - MEXC
Neurocrine Biosciences Close to $2.5B Acquisition of Soleno Therapeutics - Meyka
Neurocrine Biosciences Agrees to Acquire Soleno Therapeutics for $2.9B - Contract Pharma
Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal - BioSpace
Soleno Therapeutics (SLNO) Faces Securities Class Action - globenewswire.com
SLNO Stock Soars Over 39% — What’s Fueling The Rally? - Stocktwits
Soleno Therapeutics to Be Acquired by Neurocrine Biosciences - tipranks.com
Neurocrine Buys Soleno To Tap High-Growth Rare Disease MarketNeurocrine Biosciences (NASDAQ:NBIX), Sol - Benzinga
Neurocrine to Buy Soleno for $2.9 Billion - wsj.com
These Stocks Are Today’s Movers: Intel, Micron, Tesla, Strategy, Netflix, Soleno, and More - Barron's
Neurocrine to Acquire Soleno, Expanding Rare Disease Portfolio - TipRanks
Breakfast News: Soleno Soars 30% On Buyout Talk - The Motley Fool
Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion in Cash - marketscreener.com
Soleno to Be Acquired by Neurocrine in $53-Per-Share Tender Offer - TradingView
Neurocrine Biosciences (NBIX) agrees to buy Soleno (SLNO) for $53/share - Stock Titan
Neurocrine to buy Soleno (NASDAQ: SLNO) in $2.9B all-cash deal - Stock Titan
Neurocrine Biosciences to Acquire Soleno Therapeutics in $53-Per-Share Tender Offer and Merger - TradingView
Neurocrine Biosciences: $2.9 Billion Acquisition Of Soleno Therapeutics To Expand Rare Disease Portfolio - Pulse 2.0
Neurocrine (NBIX) to acquire Soleno in $2.9B rare-disease portfolio deal - Stock Titan
Neurocrine will pay $2.9B for Soleno and its Prader-Willi medicine - Endpoints News
Stocks making the biggest moves premarket: Netflix, Soleno Therapeutics, Strategy & more - CNBC
Soleno Acquisition: Assessing The $50 Per Share Price Tag (NASDAQ:SLNO) - Seeking Alpha
Neurocrine to acquire Soleno Therapeutics, expanding its endocrinology and rare disease portfolio - marketscreener.com
Neurocrine To Acquire Soleno Therapeutics, Expanding Its Endocrinology And Rare Disease Portfolio - TradingView
Neurocrine to buy Soleno Therapeutics for $2.9 billion By Reuters - investing.com
Neurocrine to buy Soleno Therapeutics for $2.9B - Breakingthenews.net
Neurocrine to buy Soleno Therapeutics for $2.9 billion - Yahoo Finance
Neurocrine to acquire Soleno Therapeutics for $2.9 billion - Investing.com
Neurocrine wants to develop new obesity drugs. It’s spending $2.9 billion on a company to accelerate that move. - marketwatch.com
A $2.9B deal gives Neurocrine the only approved Prader-Willi hunger drug - Stock Titan
Neurocrine nears over $2.5B deal to acquire Soleno Therapeutics, FT reports - TipRanks
Soleno Therapeutics Slides Despite Multi-Billion Buyout Talks - tipranks.com
Soleno Therapeutics (SLNO) Stock Soars 30% on $2.5B Neurocrine Acquisition News - Blockonomi
These Stocks Are Today's Movers: Intel, Micron, Paramount, Strategy, Soleno Therapeutics, and More -- Barrons.com - Moomoo
Neurocrine to acquire Prader-Will drug in $2.9B Soleno buyout - Yahoo Finance
M&A News: Soleno Therapeutics Stock (SLNO) Surges 28% as Neurocrine Biosciences Lines up $2.5B Deal - tipranks.com
SG Americas Securities LLC Increases Position in Soleno Therapeutics, Inc. $SLNO - MarketBeat
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):